Industry commits to continued efforts to protect biodiversity at close of COP17
On the occasion of the 17th session of the Convention on Biological Diversity Conference of the Parties (COP17), Guilherme Cintra, Director, Innovation Policy, IFPMA said:
“The pharmaceutical industry plays a central role in protecting health and recognizes that fulfilling this mission requires a healthy and biodiverse planet.
“For this reason, we have long supported the goals of the Convention on Biological Diversity and our member companies continue to deliver against the targets set out in the Global Biodiversity Framework through company initiatives and decades of pre-competitive collaboration.
“COP17 has underscored both the urgency of accelerating progress toward the 2030 biodiversity targets and how much work remains to develop mechanisms that would enable industry to engage meaningfully and contribute. Much of that work has been pushed into the two years leading up to COP18, which should focus on practical, evidence-based solutions that support both biodiversity and scientific development.”
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
